[Changes in parameters of the coagulation and fibrinolysis system of the blood in patients with prostate cancer in the framework of estrogen therapy].
In the authors' study it is shown that the mechanism of cardiovascular complications arising in prostatic cancer (PC) patients on estrogen therapy works through developing defects in coagulation which result in hypercoagulation and deterioration of blood rheology due to enhanced platelet aggregation. Activation of fibrinolytic enzymes seems to be an adaptive reaction decreasing hypercoagulation. The authors believe it necessary to evaluate cardiovascular and coagulative systems of PC patients before estrogen therapy to define the risk of probable complications, to design adequate prophylaxis and treatment with coronary-active and antihypertensive drugs, heparin, acetylsalicylic acid which help to prevent relevant cardiovascular complications and improve outcomes of the disease.